Pills, lozenges or tablets (A61K9/20)

Composition including amlodipine and losartan having improved stability // 2628538
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for cardiovascular disorders prevention and treatment is described. The said composition comprises amlodipine besylate in an amount of 1.7 to 1.72 wt %, potassium losartan in an amount of 12.22 to 12.37 wt %, and propyl gallate in an amount of 0.01 wt %, based on the total weight of the composition. The said composition has the form of a two-layer pill having two separate layers consisting of an amlodipine layer containing amlodipine besylate and propyl gallate and a layer of losartan containing potassium losartan.EFFECT: improved composition stability in combination with simplicity of preparation.6 cl, 21 tbl, 2 dwg, 5 ex

ethod of production of a combined antihelmint tablet with a symbiotic treatment for treatment of a small cattle // 2627893
FIELD: veterinary medicine.SUBSTANCE: invention is a method for producing a combined anthelmintic tablet with a symbiotic for treating small cattle containing a first and second layer comprising the steps of: adding a first powder mixture to a mould plate. Mentioned first powder mixture contains a pharmaceutically active substance and a binder, a second powder mixture is added to said mould plate. Mentioned second powder blend comprises a binder and the composition of mentioned second powder blend is different from the composition of mentioned first powder mixture, the first powder mixture and the second powder blend are pressed on said plate of the mould to form a tablet form and subjected to said tableted form with radio frequency emission for a period of Time sufficient to activate said binder within said tablet mould to fuse mentioned tableted Th form into said tablet, such that the density of mentioned tablet is less than about 0.8 g/cm3, characterized in that a bacterial concentrate is prepared for the preparation of the first powder mixture comprising a bifidobacterium adolescentis B-1 and Lactobacillus acidophilus LH-1 consortium with a titre of 108-1010 CFU/g sorbed on a carrier in a ratio of 1:1:12, which Is concentrated by filtration or centrifugation to a suspension containing 5 billion bacteria per ml, followed by mixing them in equal volumes. As the carrier, flour or bran is used at the rate of 12 parts of the support per part of a mixture of concentrated cultures, and then the obtained dry powder mass is mixed with lactulose, and to obtain the second powder mixture, ivermectin, praziquantel and at least one pharmaceutically acceptable excipient microcrystalline cellulose MCC is used, then the substances ivermectin, praziquantel and excipient are mixed in dry kind. The components in the tablet are in a certain ratio in wt %.EFFECT: invention provides high anthelmintic activity, intensification of treatment and prevention of a number of helminthic invasions, nonspecific correction of the immune response of the animal organism, normalization of hepatoprotective and reparative liver functions.6 ex, 1 tbl, 1 dwg

Preparations of {2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl} amide of cyclopropanecarboxylic acid // 2627471
FIELD: pharmacology.SUBSTANCE: invention relates to an oral dosage form comprising an amorphous dispersion of {2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} amide of cyclopropanecarboxylic acid or a pharmaceutically acceptable salt thereof in a hydrophilic polymer, wherein the hydrophilic polymer is hydroxypropylmethylcellulose. Also, methods for treatment, control or prevention of various diseases such as cancer or inflammatory disease are proposed.EFFECT: creation of a dosage form with rapid disintegration, reduced friability, content uniformity, rheological properties required for production, solubility, bioavailability, stability and desired hardness.9 cl, 4 dwg, 2 tbl, 1 ex
Starch-free soft chewing gums // 2627420
FIELD: pharmacology.SUBSTANCE: group of inventions refers to a soft chewing gum, which comprises: (a) a pharmaceutically effective amount of at least one active ingredient; (b) a flavoring agent of animal origin; (c) at least 10 wt % of a disintegrating agent in the final composition, which is selected from the group consisting of i) carmellose calcium, ii) directly compressible mannitol, and iii) a mixture or combination of croscarmellose sodium and directly compressible mannitol; (d) at least 10 wt % of a wetting agent in the final composition; (e) a binding agent; (f) an antioxidant; (g) optionally, a preservative; and (h) water; where the soft chewing gum contains less than about 2 wt % of each of polyethylene glycol (PEG), propylene glycol, starch, soy products and wax. Also, the group of inventions refers to a method for the said soft chewing gum production.EFFECT: short time of soft chewing gum decomposition, retained even after prolonged storage at elevated temperature.11 cl, 1 ex, 4 tbl, 3 dwg
Tablet comprising dehydroepiandrosterone (dhea) // 2627111
FIELD: pharmacology.SUBSTANCE: group of inventions relates to tablet for preventing the loss of testosterone, for maintaining physiological levels of androgens, improving sexual function, mood and health, having a weight of 60-120 mg and consisting of: - 60-100 wt % of granules consisting of: 60-85 wt % of dehydroepiandrosterone (DHEA) granules; 6-35 wt % of microcrystalline cellulose granules; 0-20 wt % of granules of one or more pharmaceutically acceptable granule ingredients; and - 0-40 wt % of one or more pharmaceutically acceptable tablet components, as well as to method of preparing the mentioned tablets.EFFECT: preparation of small tablets with a high content of DHEA, having acceptable release profile.18 cl, 10 ex
Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophene-5-yl)etoxy)propyl)azetidine-3-ol or its salt // 2625767
FIELD: pharmacology.SUBSTANCE: solid pharmaceutical formulation as a pill, comprising 1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)azetidine-3-ol or a salt thereof in an amount of 30% to 90% The said pill also contains a component selected from mannitol, sorbitol and isomaltose in an amount of 6% to 60% by weight, and a disintegrant selected from the group consisting of cellulose derivatives, starch derivatives and polypyrrolidone derivatives in an amount of 3% to 10% by weight.EFFECT: invention provides excellent solubility, hardness for dosage forms and increased stability in long-term storage.11 cl, 15 ex, 5 tbl
Pharmacological composition on basis of iron compounds // 2625739
FIELD: pharmacology.SUBSTANCE: invention is a pharmacological composition containing the iron (II) sulphate for treatment of iron deficiency anemia, characterised in that it additionally contains iron hexacyanoferrate, iron-potassium hexacyanoferrate, potassium sulfate and micro cellulose, the components in the composition being in a certain ratio, in weight percent.EFFECT: high therapeutic efficacy, good tolerability, and low toxicity.2 cl, 5 ex

Pharmaceutical composition with anti-therapeutic activity and method of its production // 2624857
FIELD: pharmacology.SUBSTANCE: composition contains 2-[(1Z)-1-(3,5-diphenyl-1,3,4-thiadiazol-2(3H)-ylidene chloride)methyl]-3,5-diphenyl-1,3,4-tiadiazol-3-th (TDZ) in an amount of 15 to 50 wt %, Polyethylene oxide, in an amount of 15 to 50 wt %, Poloxamer, in an amount of 5 to 20 wt % Lecithin, in an amount of 1 to 5 wt %, and pharmaceutically acceptable excipients. According to the process for preparing the composition, the TPD is dissolved in ethyl or isopropyl alcohol, methylene chloride or mixtures thereof, polyethylene oxide, poloxamer and lecithin are introduced into the solution, then other pharmaceutically acceptable excipients are added to the mixture, the mixture is dried, granulated, and tablets or capsules are prepared.EFFECT: inventions allow to increase the release of the active substance from the tablet or granules and to improve the antifungal activity of the substance.6 cl, 1 dwg, 3 tbl, 6 ex

Pharmaceutical composition containing tetrahydropholic acid // 2624236
FIELD: pharmacology.SUBSTANCE: oral dosage form comprises progestogen, estrogen, 5-methyl-(6S)-tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient or carrier, and comprises granulating of progestogen and estrogen and at least one pharmaceutically acceptable excipient in the fluidized bed, mixing of 5-methyl-(6S)-tetrahydrofolic acid or the pharmaceutically acceptable salt thereof with granules, and further granulation by maintaining the fluidized bed and formation of a solid oral dosage form from granules.EFFECT: compositions of the invention provide good stability of tetrahydrofolic acid during storage and at the same time provide a rapid release of estrogen and progestogen present in the composition.14 cl, 3 dwg, 5 tbl, 6 ex
Pharmaceutical composition containing memantine and melatonin combination // 2623865
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition in the form of a pille dispersed in the mouth, containing: 2.0 to 15.0 wt % of memantine; 1.0 to 10.0 wt % of melatonin; 65.0 to 80.0 wt % of the filler selected from mannitol or mannitol mixture with copovidone; 4.0 to 15.0 wt % of desintegrant, selected from crospovidone; 1.0 to 2.0 wt % of the binding substance, selected from sorbitol; 1.0 to 2.5 wt % of the sweetener selected from maltitol, sodium saccharinate, or a mixture thereof; 0.5 to 1.0 wt % of the sliding substance selected from colloidal silicon dioxide, stearic acid, magnesium stearate, talc or mixtures thereof; 1.5 to 3.0 wt % of flavor, as well as a production method.EFFECT: expansion of the arsenal of pharmaceutical compositions containing a combination of memantine and melatonin, increased storage stability and dissolution rate.12 cl, 6 ex
Pharmaceutical composition for sleep disorders prevention and treatment // 2620855
FIELD: pharmacology.SUBSTANCE: invention relates to a pharmaceutical composition for sleep initiating and maintaining and prophylaxis of animal and human states that are accompanied by sleep disorders of a different nature, including a combination of active agents consisting of 0.5-45 mg of doxylamine succinate and long-acting melatonin in amount of 0.1-20 mg.EFFECT: synergistic therapeutic effect and reduced side effects.2 cl, 1 tbl, 5 ex
Composition containing paracetamol and glutathione, and method for its obtaining // 2620340
FIELD: pharmacology.SUBSTANCE: analgesic composition for oral administration is proposed, comprising from 1 to 15 wt % of reduced glutathione, and from 5 to 45 wt % of paracetamol as active agents. The composition described in the present invention can be used for preparing various medicinal forms in accordance with conventional methods of formulating, such as tablets, slow acting agents/agents with controlled release, capsules, pills, syrups, film-forming agents, granules, oral solutions, oral suspensions, emulsions, oral powders, and any other pharmaceutically acceptable medicinal forms.EFFECT: compositions described in the present invention can not only effectively prevent the damage and necrosis of liver cells caused by paracetamol overdose, but also provide a good effect of treating pain in cancer and chemotherapy.7 cl, 3 ex
Implantable naltrexone tablets // 2620254
FIELD: medicine.SUBSTANCE: implantable naltrexone tablets and method for sterilizing implantable naltrexone tablets are described. The implantable tablet comprises naltrexone in an amount of 500-2000 mg placed in a cavity formed by moulded biodegradable polymer based on DL-lactides and/or DL-glycolides, adding Eudragit pharmaceutical polymer and a lubricant to provide controlled release of the active substance for 3 months or more. The lubricant consists of stearic acid or glyceryl monostearate to prevent tissue irritation and inflammation at the implantation site.EFFECT: implantable naltrexone tablets, free of magnesium stearate and triamcinolone, are obtained, in order not only to reduce the metabolic load on the liver, but also reduce toxicity and carcinogenicity.7 cl, 2 tbl, 6 ex
Solid pharmaceutical form of immediately releasing zafirlukast and method of its production // 2619213
FIELD: pharmacology.SUBSTANCE: invention relates to a solid pharmaceutical form of zafirlukast having anti-inflammatory, anti-asthmatic, bronchospasm-warning action, which is a coated tablet containing zafirlukast and target additives at the following component ratio, %: core: zafirlukast - 7.8-10.2, calcium hydrophosphate dihydrate - 25.0-35.0, Prosolve - 22.0-40.0, hypromellose - 3.0-8.0, pregelatinized starch - 10.2-25.5, croscarmellose sodium - 1.0-3.0, aerosil - 0.5-3.0, stearic acid and/or its salts - 0.5-1.0; shell: hypromellose - 0.5-1.4, titanium dioxide - 0.3-0.6, macrogol - 0.1-0.6. The invention also relates to a process for preparation of a solid form of zafirlukast which includes a direct compression method.EFFECT: invention allows to obtain solid forms of zafirlukast, in particular in the form of pills, characterized by good disintegration and strength, as well as rapid solubility.10 cl, 3 tbl
Combined preparation of lercanidipine and atorvastatin // 2617048
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and pharmacy. Combined preparation of lercanidipine hydrochloride and calcium atorvastatin is disclosed for treating hypertension accompanied by hyperlipidemia, which contains single dose of 5–20 mg of lercanidipine hydrochloride and 10–80 mg of atorvastatin calcium, wherein weight ratio of lercanidipine hydrochloride to atorvastatin calcium is 1:2–4, and method of producing coated tablet containing them.EFFECT: technical result is combined preparation of lercanidipine and calcium atorvastatin according to this invention has higher efficiency at lower dose as compared to combined introduction of tablets with respect to considerable reduction of hypertension and reducing level of lipids; it is characterized by low therapeutic dose and reduction of number of undesired effects, as well as good tolerance and compliance with drug therapy regimen of patients.8 cl, 7 tbl

ethod of medicinal herb tabletting // 2616905
FIELD: pharmacology.SUBSTANCE: method of medicinal herb tabletting comprising grinding of the medicinal herb, drying and tabletting, wherein the flows of sprayed ground medicinal herb and sprayed solution of starch dextrins are mixed, thereby covering particles of the medicinal herb with starch dextrins film, the medicinal herb is dried in starch dextrins, the dried material in starch dextrins is splashed with water vapour before tabletting.EFFECT: method enables to reduce the loss of herbal raw material active agents, facilitates rapid disintegration in the gastrointestinal tract.2 dwg
Liquid lubricant for tableting, integrated into tablets // 2615823
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical and nutriceutical tablets. Method of producing tablets includes provision of matrix with liquid lubricant included in its composition, containing oily fluid finely dispersed in oil-insoluble material, provision of composition of food additive or pharmaceutically active composition, mixing of matrix with liquid lubricant included in its composition and composition of food additive or pharmaceutically active composition and formation of tablet. Wherein matrix with liquid lubricant included in its composition ranges from 0.3 % to 8.8 % of tablet, and composition of food additive or pharmaceutically active composition contains no stearate.EFFECT: invention allows to improve lubrication of dry nutraceutical and/or pharmaceutical compositions for tabletting.21 cl, 2 tbl, 3 ex

Antibacterial agents and method for treating intestinal yersiniosis or pseudotuberculosis, or colibacillosis // 2614730
FIELD: pharmacology.SUBSTANCE: antibacterial agent comprises a calcium lactate in the effective therapeutic dose. The treatment method comprises the enterally introduced antibacterial agents.EFFECT: increasing the therapeutic agent and method activity by increasing the intestinal colonization resistance, eliminating dysbiosis and preventing morphofuctional disorders of the intestinal mucosa.7 cl, 1 dwg, 2 tbl

Pharmaceutical composition for oral administration containing statin // 2614728
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical composition for oral administration containing or consisting of: (i) from 11 to 25 wt% of simvastatin, (ii) from 0.01 to 3 % by weight of first substance (A1) with antioxidant activity, which is butylhydroxyanisole, (iii) from 0.01 to 3 % by weight of second substance (A2) with antioxidant activity, differing from first substance (A1) with antioxidant activity, which is citric acid, and (iv) from 75 to 85 wt% of at least one additive selected from group consisting of filler, binder, agents for controlling fluidity, baking powder and agent preventing adhesion or combinations thereof, where quantitative ratio of butylhydroxyanisole (A1) and citric acid (A2) ranges from 1:95 to 1:30, and wherein above composition is compacted in form of tablet and said tablet has mass from 130 to 300 mg.EFFECT: invention also relates to use of said pharmaceutical composition in medicine.12 cl, 2 ex, 4 tbl, 5 dwg
Pharmaceutical composition comprising fimasartan and hydrochlorothiazide // 2613900
FIELD: medicine, pharmacy.SUBSTANCE: pharmaceutical composition comprises 132.02 mg of potassium fimasartan trihydrate, 12.5 mg of hydrochlorothiazide and a binder, which binding solution has a viscosity from 20 mPa·s to 650 mPa·s. The binder includes at least one substance selected from the group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose and polyvinylpyrrolidone. A method for preparation of a pharmaceutical composition by wet granulation and a pill obtained in this manner are also described. This composition is characterized by a standard deviation (RSD) of 4.0% or less in the content uniformity test of the active ingredients. The uncoated pill has a crush strength of 7 Kp or more as per the invention.EFFECT: invention refers to a pharmaceutical composition in the form of pill for hypertension treatment.9 cl, 12 tbl, 11 ex
Biologically active composition in form of lozenge // 2613180
FIELD: biotechnology.SUBSTANCE: biologically active composition in the form suitable for oral resorption, contains L-theanine or diosgenin or a dry extract of Dioscorea villosa (wild yam) rhizomes containing these substances in effective amounts, and auxiliaries. The lozenges provide higher diosgenin bioavailability.EFFECT: improved condition in case of physical fatigue of various origins.2 cl, 4 ex
Solid preparations containing pelargonium sidoides extracts and silicic acid compounds and production methods // 2612085
FIELD: pharmacy.SUBSTANCE: solid preparation for respiratory diseases treatment, containing a Pelargonium sidoides extract and calcium silicate in a specific weight ratio. A method for solid preparation production for respiratory diseases treatment.EFFECT: increased hardness and reduced abrasion.6 cl, 4 tbl
Dispersible in water acetylcysteine tablet and method of manufacturing thereof // 2611411
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to field of pharmaceutics. Described is dispersible in water acetylcysteine tablet, which contains from 100 to 600 mg of said substance and auxiliary components, taken in ratio 1:1 to the total weight from 200 to 1200 mg. Active and auxiliary substances are used in the following weight ratio, %: acetylcysteine - 50.0; microcrystalline cellulose - 34.1; lactose monohydrate - 5.0; crospovidone - 5.0; povidone - 25-2.0; lemon flavour - 1.0; sodium saccharinate - 0.825; aspartame - 0.675; citric acid monohydrate - 0.325; colloidal silicon dioxide - 0.75; magnesium stearate - 0.75. Tablet is capable of dispersing in water at temperature 15-25°C within 3 minutes with formation of dispersion, consisting of particles with size smaller than 710 mcm.EFFECT: obtained tablet possesses high stability and physical preservation, good mechanical properties in combination with fast disintegration in water solutions.2 cl, 3 ex, 4 tbl
Drug based on tetrametiltetraazobitsiklooktandion and method for its production // 2611194
FIELD: pharmacy.SUBSTANCE: here is a description of dosage form of tetrametiltetraazobitsiklooktandion, additionally containing a filler, granulating agent, lubricant, disintegrant, flavoring agent in certain weight ratios. Methods of preparing of the said dosage form are also described.EFFECT: preparation of the dosage form without defects in manufacture and storage and with improved taste characteristics.11 cl, 3 tbl
Anti-inflammatory composition with prolonged action for treating airway // 2608126
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and concerns anti-inflammatory composition for treating upper airways. Anti-inflammatory composition for treating upper airway in form of tablets containing echinacea dry extract, evkalimine, colloidal silicon dioxide, sodium stearyl fumarate, dextrose monohydrate, taken in certain amount.EFFECT: composition described above, in form of tablets, has high pharmaceutical activity with respect to treating upper airways, it is stable during storage.1 cl, 1 tbl, 2 ex

Destruction-resistant dosage form containing anionic polymer // 2607499
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics, namely to dosage form in form of tablets with tensile strength of at least 500 N containing pharmacologically active component (A) selected from hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, tramadol and their pharmaceutically acceptable salts; polymer (B) selected from (i) homopolymer of acrylic acid, cross-linked allyl sucrose or allyl pentaerythritol, or (ii) copolymer of acrylic acid and C10-C30-alkyl-acrylate, cross-linked allyl pentaerythritol, or (iii) interpolymer selected from homopolymers of acrylic acid, cross-linked allyl sucrose or allyl pentaerythritol, and copolymers of acrylic acid and C10-C30-alkyl-acrylate, cross-linked allyl pentaerythritol containing copolymer block of polyethylene glycol and ester of C8-C30-alkyl acid; and from 30 to 90 wt% of polyethylene oxide (C) with average molecular weight from 2,500,000 to 15,000,000 g/mol, wherein component (A) is present in controlled-release matrix containing polymer (B) and polyethylene oxide (C).EFFECT: invention provides production of destruction-resistant dosage forms with prolonged release of active component.5 cl, 8 ex, 19 tbl, 16 dwg
Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs // 2606845
FIELD: pharmaceutics.SUBSTANCE: group of inventions refers to medicine and pharmacology, and can be used for preparing solid pharmaceutical composition, wherein the solid pharmaceutical composition contains: (i) amorphous solid solution of 9-[2-[bis[(pivaloiloxy)-methoxy]phosphinyl]methoxy]ethyl]adenine (AD) and a copolymer of vinylpyrrolidone and vinyl acetate and (ii) one or more pharmaceutically acceptable inactive ingredients selected from microcrystalline cellulose, silicon dioxide and magnesium stearate, wherein the solid pharmaceutical composition is stable, such that when the solid pharmaceutical composition is stored at 40 °C and relative humidity of 75 % in a closed container for 3 months, amount of impurities presented in the solid pharmaceutical composition, is not more than 0.74 weight. % in relation to the initial number of AD, wherein the admixture is 9-[2-(pivaloiloxy)-methoxyphosphinyl]methoxy]ethyl]adenine; at that, the method comprises the following steps: (i) producing amorphous solid solution of AD and copolymer of vinylpyrrolidone and vinyl acetate by dissolving the initial quantity of AD and copolymer of vinylpyrrolidone and vinyl acetate in a volatile organic solvent selected from ketones and halocarbons, evaporation of the volatile organic solvent and (ii) dry mixing of the obtained amorphous solid solution with one or more pharmaceutically acceptable inactive ingredients. Solid pharmaceutical composition and packing system are also disclosed.EFFECT: group of inventions ensures production of highly-stable composition having storage stability.10 cl, 5 tbl, 3 ex
Pharmaceutical composition containing rosuvastatin calcium salt (versions) // 2606592
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and medicine, namely to production of medicinal preparations for treating hypercholesteremia, atherosclerosis, lipid storage disease. 4 versions of pharmaceutical composition are proposed. According to 2 versions pharmaceutical composition contains calcium rosuvastatin in amount of 5 mg or 10, 20 or 40 mg and as auxiliary substances it has microcrystalline cellulose, mannitol, calcium dihydrophosphate, corn starch, talc, magnesium stearate. According to other 2 versions pharmaceutical composition contains calcium rosuvastatin in amount of 5 mg or 10, 20 or 40 mg and as auxiliary substances it has microcrystalline cellulose, mannitol, crospovidone, talc, magnesium stearate. Pharmaceutical composition is presented in form of tablet, film-coated, or in form of capsules.EFFECT: invention widens range of drugs for treating lipid storage disease, atherosclerosis, hypercholesterinemia.20 cl, 14 tbl

Pharmaceutical composition having immunostimulating action // 2605832
FIELD: medicine.SUBSTANCE: invention relates to medicine and pharmacy, more specifically to a pharmaceutical composition, having immunostimulating action. Pharmaceutical composition contains N-{2-[3,4-bis-(4-nitrobenzoyloxy)phenyl]ethyl}-4-nitrobenzamine(fentral) as an active substance. Target additives used can be optionally simultaneously corn starch, hydroxypropyl cellulose, microcrystalline cellulose, calcium dihydrophosphate, polyvinyl pyrrolidone, sodium croscarmellose, lactose, sodium benzoate, magnesium stearate, calcium stearate, sorbitol, mannitol. Pharmaceutical composition can be made in form of tablets or capsules. Tablets and capsules with fentral meet State Pharmacopoeia requirements.EFFECT: medicinal agent with fentral has immunostimulating action.1 cl, 6 tbl, 6 ex

Agent for dissolution of bile stones and treatment of cholelithiasis // 2605264
FIELD: medicine; veterinary.SUBSTANCE: invention relates to human and veterinary medicine, namely to means for dissolution of bile stones and treatment of cholelithiasis. Agent for dissolution of bile stones and treatment of cholelithiasis contains mixture of varied polyprenyl phosphates and/or polyprenyl pyrophosphates of vegetal origin with number of isoprene links from 7 to 30. Agent can be absorbed on solid sorbent, in particular sorbitol, lactose, starch, and can contain beta-sitosterol.EFFECT: technical result from use of proposed drug consists in possibility of dissolution of bile stones and treatment of cholelithiasis with no adverse reactions.12 cl, 7 dwg, 2 tbl, 3 ex

Destruction-resistant dosage form containing an inorganic salt // 2604676
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics, namely to a pharmaceutical dosage form with breaking strength of at least 500 N, mentioned dosage form contains pharmacologically active component (A); inorganic salt (B), where inorganic salt (B) is sodium carbonate or five-substituted sodium triphosphate or mixture of them, and content of inorganic salt (B) ranges from 15 to 40 wt%, based on total weight of dosage form; and polyalkylene oxide (C), having weight-average molecular weight of at least 200.000 g/mol, where content of polyalkylene oxide (C) is at least 30 wt% of total weight of dosage form; where pharmacologically active component (A) is present in controlled-release matrix containing inorganic salt (B) and polyalkylene oxide (C) and where in vitro, release profile of pharmacologically active component (A) from mentioned matrix includes at least, time interval during which release corresponds to zero-order kinetics.EFFECT: stated pharmaceutical dosage form is suitable for avoiding abuse of pharmacologically active component, which is contained in it.10 cl, 3 ex, 5 dwg
Composition with simeticon // 2602745
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents pharmaceutical composition including mixture of: (a) simeticon, from 10 to 20 wt.% of composition weight, (b) calcium phosphate powder, 20 to 40 wt.% of composition weight, and (c) mannitol, from 30 to 50 wt.% of composition weight, where weight ratio of mannitol to calcium phosphate powder is at least 1:1.EFFECT: invention provides synergetic effect, which consists in high stability against disintegration in stress conditions, as well as excellent fluidity and compressibility properties.12 cl, 2 ex, 3 tbl

Pharmaceutical composition of n-(6-phenylhexanoyl)glycyl-l-tryptophan amide in solid dosage form // 2602742
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to pharmacy, and concerns pharmaceutical composition in solid dosage form and containing therapeutically effective amount of N-(6-phenylhexanoyl)glycyl-L-tryptophan amide as medicinal substance, and auxiliary substances, which are binding agent of group of substances providing sufficient weight of tablet or capsule: cellulose or cellulose derivatives, such as microcrystalline cellulose; lactose, polyvinylpyrrolidone, calcium carbonate, calcium phosphate; auxiliary substances with high sorption capacity: colloidal silica, magnesium aluminometasilicate; group of sliding agents - stearic acid and/or its salts, surfactants: sodium oleate, sodium lauryl sulphate; disintegrants from group: starch, pectin, polyvinyl pyrrolidone, sodium croscarmellose, sodium carboxymethyl cellulose.EFFECT: tablets and capsules meet all requirements of State Pharmacopeia XI and XII edition and have high bioavailability of above therapeutic peptide.1 cl, 3 dwg, 2 tbl, 16 ex

Enterosorbent // 2602699
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and represents enterosorbent in form of tablet, containing 25-35 wt% of colloidal silicon dioxide, 15-33 wt% of microcrystalline cellulose, rest is auxiliary substances, which includes substance, serving for preparation of a humidifier in production of tablets, characterized by fact, that enterosorbent contains sorbitol as said auxiliary substance in amount of 20-30 % of tablet weight.EFFECT: invention provides increase of sorption capacity of enterosorbent by 10-15 %.3 cl

Solid molecular dispersion // 2600816
FIELD: pharmaceutics.SUBSTANCE: group of inventions relates to pharmaceutical industry, in particular, to a pharmaceutical solid molecular dispersion, with ratio fesoterodine hydrogen fumarate: alkyl hydroxyalkylcellulose ether or hydroxyalkylcellulose ether, or an ester of either thereof, or a mixture of any two or more thereof, ranging from 3:97-12:88 wt%, method of production thereof, as well as to a pharmaceutical inert granule or particle, which is a core, which is coated with said dispersion and a pharmaceutical composition, including in form of tablets containing such granules. In one embodiment fesoterodine hydrogen fumarate is stabilised in dispersion in a form, which not correspond to its crystalline or amorphous form.EFFECT: group of inventions provides high chemical stability of compositions containing fesoterodine hydrogen fumarate.24 cl, 12 ex, 27 tbl, 19 dwg

Form of pharmaceutical composition multi-layer coating for oral administration containing omega-3 fatty acid or its alkyl ester, as well as medicinal agent based on statin // 2600804
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics. Pharmaceutical composition for oral administration is described containing: gelatine capsule core, coated with first and second layers of coating. Gelatine capsule core contains omega-3 fatty acid or its alkyl ester. First coating layer contains hydroxypropyl methylcellulose and copolymer of butyl methacrylate, (2-dimethylaminoethyl)methacrylate and methyl methacrylate with weight ratio of 1:2:1; where weight ratio of hydroxypropyl methylcellulose to said copolymer ranges from 1:0.8 to 1:10. Second coating layer contains medicinal agent based on statin as inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase.EFFECT: invention prevents sticking of gelatine capsules' cores to each other and deformation of gelatin capsules' cores, which can occur in process of aqueous coating application, invention also provides pharmaceutical composition disintegration and stability requirements compliance.13 cl, 9 tbl, 7 ex

Solid compositions containing agonist to glp and salt of n-(2-hydroxybenzoyl)amino)caprylic acid // 2600440
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions concerns solid compositions containing agonist GLP-1 and salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, where the amount of said salt is at least 0.6 or at least 0.8 mmol, and said GLP-1 agonist represents semaglutide, as well as use in medicine for treating type II diabetes or obesity.EFFECT: group of inventions provides improved action and bioavailability.28 cl, 1 ex, 10 tbl

Coating composition suitable for pharmaceutical or nutriceutical dosage forms // 2599023
FIELD: pharmaceutics.SUBSTANCE: invention relates to a coating composition suitable for coating pharmaceutical or nutriceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition, derived from an emulsion polymerisation process, wherein the core of the core/shell polymer composition is formed by a water-insoluble, cross-linked polymer or copolymer, containing polymerised links of n-butyl acrylate, n-butyl methacrylate or methyl methacrylate and ethylene glycol dimethacrylate, and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer, containing polymerised links from 10 to 40 wt% of acrylic or methacrylic acid, from 10 to 50 wt% of ethyl acrylate and from 10 to 80 wt% C4-C18-alkyl Ester of acrylic acid or methacrylic acid.EFFECT: coating of the dosage form.13 cl, 3 tbl

Tableted drug based on the extract of alchemilla vulgaris // 2599020
FIELD: medicine.SUBSTANCE: invention relates to tableted drug for the treatment of syndrome of increased blood viscosity. Agent includes 6 wt% of thick extract of Alchemilla vulgaris, obtained by evaporation of alcoholic extract to a residual humidity of 25 %, 46.8 wt% of glucose, 46.8 wt% of lactose, 0.1 wt% of calcium stearate and 5 % aqueous solution of methylcellulose - the rest.EFFECT: invention ensures production of tablets with high strength, high stability during storage and satisfying the requirements of the current pharmacopoeia.1 cl, 2 tbl, 1 ex

ethod of producing extract of castoreum for production of biologically active additives (versions) // 2598706
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely to a method of producing an extract of castoreum and biologically active additive of it. Method of producing an extract of castoreum for production of biologically active food additive with bracing, tonic, immunomodulatory action, involving bucking of pre-dried castoreum up to homogeneous fine powder, then powder is extracted with water solution of ethyl alcohol, mixture is maintained without access of light, extract is separated by filtration, extraction is carried out at least 3 times, at that, the last extraction is carried out using ultrasound, then extracts obtained after each filtration, are mixed and boiled out under certain conditions. Biologically active additive (BAA) to food - in the form of a tablet. Biologically active food additive - in the form of capsules.EFFECT: method described above allows to produce BAAs, having bracing, tonic and immune modulating properties.3 cl, 1 tbl, 3 ex

Implantable device for controlled release of drug with low solubility // 2598057
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine. Implanted drug delivery device comprises element containing a medicinal agent, which includes a solid unit of a medicinal agent, containing a medicinal agent and casing with a defined hole. Defined hole is made with sizes that allow locking of said solid drug unit, as a result of which said casing encloses a first part of surface of solid drug unit and exposes a second part of surface of solid drug unit. Device is elastically deformable from a relatively straightened shape suited for insertion through a lumen into a body cavity of a patient and a retention shape suited to retain device within body cavity. Device is configured for controlled drug release by erosion of exposed second part of surface of at least one solid drug unit. Also disclosed are versions of device for drug delivery, having structural differences, and a method of local drug delivery.EFFECT: technical result consists in delivery of medicines with low solubility in effective release doses.30 cl, 44 dwg

Pharmaceutical compositions containing dgat1 inhibitor // 2595866
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a pharmaceutical composition in form of a tablet containing a) therapeutically effective amount of sodium salt (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, b) sodium lauryl sulphate as a surfactant with properties of lubricant substance in amount of 0.1 to 5 %, c) low-substituted hydroxypropyl cellulose in dry binder with properties of baking powder in amount of 2 to 20 %, d) mixture of microcrystalline cellulose and anhydrous lactose as filler in ratio of 1:5 to 1:1 and e) sodium starch glycolate as a disintegrant in amount of 1 to 10 % by weight of tablet before application of film coating. Invention also relates to a method of preparing a pharmaceutical composition and use thereof as a medicinal agent.EFFECT: compositions demonstrate compression profile with a wide hardness window, which provides acceptable brittleness, hardness, decomposition and dissolution time and sufficient stability to achieve rational storage life.10 cl, 10 ex

Antisense compositions and methods for production and use thereof // 2593939
FIELD: biotechnology. SUBSTANCE: present invention relates to biotechnology and represents pharmaceutical formulations for oral administration of anti-sense oligonucleotide against SMAD7, pharmaceutically acceptable tablets for oral application of anti-sense oligonucleotide against SMAD7, as well as oral dosage form containing said antisense oligonucleotide and enteric coating containing ethyl acrylate-copolymer of methacrylic acid. Said pharmaceutical formulations, pharmaceutically acceptable tablets and oral dosage form is used for treating Crohn's disease, ulcerative colitis and other chronic inflammatory intestinal diseases in patient by oral administration. EFFECT: present invention enables directed delivery of anti-sense oligonucleotide against SMAD7 terminal ileum and ascending colon division of patient for effective treatment of chronic inflammatory intestinal diseases. 23 cl, 7 dwg, 7 tbl, 9 ex

Agent for reduction of intestinal microbiocenosis in case of dysbiosis // 2593584
FIELD: pharmaceutics. SUBSTANCE: invention relates to pharmaceutics. Described is use of calcium lactate for restoration of intestinal microbiocenosis in case of dysbiosis in an effective therapeutic daily dose of 0.5-1.5 g for an adult. EFFECT: invention provides fast normalisation of composition and amount of intestinal microflora in case of dysbiosis. 1 cl, 6 tbl

Antiviral and immunostimulating drug // 2593570
FIELD: pharmaceutics. SUBSTANCE: described are 3 versions of antiviral and immunostimulating drugs in form of a film-coated tablet, consisting of active substance methylphenylthiomethyl-dimethylaminomethyl-hydroxybromoindole carboxylic acid ethyl ester (umifenovir), auxiliary substances of tablet-core and film shell. EFFECT: higher storage stability of said drug. 18 cl, 4 tbl

Pharmaceutical compositions containing 3-(2, 2-difluorobenzo[d][1, 3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridine-2-yl)benzoic acid, and administration thereof // 2592368
FIELD: pharmaceutics. SUBSTANCE: pharmaceutical composition containing the compound 1,3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridine-2-yl)benzoic acid, and at least one excipient selected from filler, diluent, disintegrating agent, surfactant, binder, imparting slipperiness substance and lubricant, wherein composition is suitable for oral administration to patient in need thereof for treating CFTR-mediated diseases, such as cystic fibrosis. Methods of patient in need treating thereof include administering. EFFECT: including compound 1 having oral pharmaceutical finished dosage form. 84 cl, 27 dwg, 18 tbl
Galenic compositions suitable for administering to animal, other than human, use thereof and related methods // 2591080
FIELD: veterinary science.SUBSTANCE: group of inventions relates to a galenic composition suitable for administering to a non-human animal, containing at least following three components: one or more active substances; agent for accelerating disintegration, representing lignosulphonate in form of water-soluble powder; substance for deceleration of disintegration, which is a fat, solid at room temperature, agent for accelerating disintegration and substance for deceleration of disintegration of composition to form a matrix with controlled release of active substance or substances. Also disclosed is use of said composition containing an active substance based on calcium and/or magnesium pidolate, which causes mobilisation of endogenous calcium ions in animals.EFFECT: group of inventions provides controlled release of active substance.23 cl, 30 tbl

Agent for treating intestinal infections and conditions caused by dysbacteriosis, "biobalance a" // 2589843
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely, to a preparation for treatment of intestinal infections and conditions caused by dysbacteriosis (versions). Preparation in liquid form consists of Lactobacillus acidophilus of strain 100 AC 1×109-1×1010 CFU/g and nutrient medium for cultivation of lactobacteria in certain ratio of components. In the form of tablets, the preparation consists of Lactobacillus acidophilus of strain 100 AC 1×1010 CFU/g, calcium stearate, talc, girasol and lactose in certain ratio of components.EFFECT: preparations described above are characterised by an increased probiotic activity, accelerated resettlement of normoflora on mucous membranes, higher stability (for 60 days).2 cl, 1 tbl, 4 ex

Pharmaceutical composition // 2589842
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a method of producing a pharmaceutical composition containing deferasirox. Method includes steps of producing dispersion of deferasirox with at least one excipient in water, homogenisation of deferasirox and at least one excipient to obtain a homogeneous dispersion of deferasirox and grinding said homogeneous dispersion until suspension with average particle size less than or equal to 2,000 nm is obtained. Also described is a pharmaceutical composition of deferasirox nanoparticles obtained using said method. Composition is intended for oral administration and is in form of a tablet. Disclosed composition is used in preparing a drug for treating chronic iron overload.EFFECT: method provides a stable and effective deferasirox composition with improved solubility.25 cl, 6 ex

Solid dosage form of preparation of sedative and hypnotic effect // 2589833
FIELD: medicine.SUBSTANCE: invention relates to a solid dosage form of sedative and hypnotic effect. Said dosage form is a tablet or capsule, which contains hydroxyzine in amount of 3.33 to 4.5 wt%, ethyl ether of α-bromo-isovaleric acid in amount of 5.47 to 7 wt%, peppermint oil or mixture thereof with hop oil in amount from 0.39 to 0.48 wt%, β-cyclodextrin in amount of 37-50 wt% and additives, including combined water.EFFECT: invention is characterised by high sedative properties and hypnotic efficiency compared to existing analogues, which provides long sleep duration and faster onset thereof.3 cl, 3 tbl, 3 ex